Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Osteopore Ltd. ( (AU:OSX) ) has issued an update.
Osteopore has signed a collaboration agreement with Singapore’s Tan Tock Seng Hospital to co-develop a novel implant for treating avascular necrosis of the hip, a progressive condition that can lead to bone collapse and total hip replacement. The 18‑month agreement builds on prior innovation grants and sets joint ownership of newly developed intellectual property, while granting Osteopore an exclusive worldwide licence to manufacture and commercialise the implant.
The arrangement strengthens Osteopore’s clinical and commercial position in regenerative orthopaedics by securing lead rights over a potentially significant solution in a niche but meaningful market, with 20,000 to 30,000 new AVN cases annually in the U.S. alone. By formalising a long-term partnership and exclusivity on future improvements, Osteopore positions itself to expand its product portfolio and capture value from any successful clinical adoption of the hip implant globally.
The most recent analyst rating on (AU:OSX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Ltd is an Australian-Singaporean regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The company focuses on developing implantable medical devices that harness tissue regeneration, targeting orthopaedic and cranio-maxillofacial indications, with an emphasis on innovative solutions for complex bone-related conditions.
Average Trading Volume: 31,878,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.86M
Find detailed analytics on OSX stock on TipRanks’ Stock Analysis page.